ARID1B

Across TCGA pan-cancer cohorts, ARID1B mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated ARID1B data layer compared with 25 for mass-spec protein and 11 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher ARID1B mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARID1B expression acts as an unfavorable survival marker, although some lineages such as COAD and LUAD show a favorable association.

COAD, HNSC, and LUAD are the cancer types where ARID1B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	All	1.000	0.915	.012	48	view →
HNSC	OS	Median	All	0.768	0.939	<.001	35	view →
LUAD	OS	Median	All	0.860	0.548	.004	8	view →
GBM	OS	Tertile	All	0.633	0.315	.023	4	view →
PDAC	OS	Tertile	III,IV	0.819	0.626	.038	4	view →
LSCC	OS	Median	II,III,IV	1.000	0.833	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

ARID1B–COAD (DFS)

Open the COAD breakdown →